Yongxin Yu

Dr. Yongxin Yu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
JWJiajing Wu
Jiajing Wu
QLQiang Liu
Qiang Liu
HXHui Xie
Hui Xie
RCRuifeng Chen
Ruifeng Chen
WHWeijin Huang
Weijin Huang
YWYouchun Wang
Youchun Wang

1 July 2018 in Vaccine
Verified
Journal Article
Closed access
XLXinyu Liu
Xinyu Liu
DZDanhua Zhao
Danhua Zhao
LJLili Jia
Lili Jia
HXHongshan Xu
Hongshan Xu
RNRui Na
Rui Na
YLYuhua Li
Yuhua Li

9 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
EFEnyue Fang
Enyue Fang
XLXiaohui Liu
Xiaohui Liu
MLMiao Li
Miao Li
JLJingjing Liu
Jingjing Liu
ZZZelun Zhang
Zelun Zhang
YLYuhua Li
Yuhua Li
Since the first isolation in 1943, the dengue virus (DENV) has spread throughout the world, but effective antiviral drugs or vaccines are still not available. To provide a more stable reporter DENV for vaccine development and antiviral drug screening, we constructed a reporter DENV containing the NanoLuc reporter gene, which was inserted into the 5′ untranslated region and capsid junction region, enabling rapid virus rescue by in vitro ligation. In addition, we established a live imaging mouse model and found that the reporter virus maintained the neurovirulence of prototype DENV before engineering. DENV-4 exhibited dramatically increased neurovirulence following a glycosylation site-defective mutation in the envelope protein. Significant mice mortality with neurological onset symptoms was observed after intracranial infection of wild-type (WT) mice, thus providing a visualization tool for DENV virulence assessment. Using this model, DENV was detected in the intestinal tissues of WT mice after infection, suggesting that intestinal lymphoid tissues play an essential role in DENV pathogenesis.

1 July 2019 in Biologicals
Verified
Journal Article
Closed access
XLXinyu Liu
Xinyu Liu
LJLili Jia
Lili Jia
KNKaixiao Nie
Kaixiao Nie
DZDanhua Zhao
Danhua Zhao
RNRui Na
Rui Na
YLYuhua Li
Yuhua Li

27 February 2025 in Processes
Verified
Journal Article
Open access
PDF file
HWHao Wu
Hao Wu
CZChenyan Zhao
Chenyan Zhao
ZCZiqi Cheng
Ziqi Cheng
WHWeijin Huang
Weijin Huang
YYYongxin Yu
Yongxin Yu
Background/Objectives: Influenza viruses are highly transmissible and mutable, posing a significant burden on public health. This study aimed to design a recombinant multi-epitope vaccine with broad protective potential. Methods: Immunoinformatic approaches were employed to predict epitopes from over 30,000 protein sequences retrieved from protein databases. Epitopes were filtered using four key indicators: antigenicity, allergenicity, toxicity, and conservancy. Population coverage analysis was conducted to estimate the proportion of the global population that could potentially benefit from the vaccine. Secondary and tertiary structures of the recombinant vaccine were predicted using the PSIPRED server and AlphaFold2. The vaccine efficacy was validated through an immune simulation, molecular docking, and molecular dynamics simulation. Results: A recombinant multi-epitope vaccine demonstrating strong antigenicity, no allergenicity or toxicity, and high conservation across different subtypes was successfully constructed. Population coverage analysis indicated that the vaccine could elicit an immune response in 90.14% of the global population. Both the secondary and tertiary structures of the vaccine were accurately predicted. Molecular dynamics simulations further validated the structural stability and interactions of the vaccine components with TRL4. Molecular docking confirmed the robust binding affinity of T-cell epitopes to MHC molecules. Simulated immunity studies showed that the vaccine induced the proliferation of memory B cells and T cells, enabling rapid antibody production during viral challenges. Conclusions: This study provides a promising basis for the development of a broadly protective influenza vaccine, leveraging cutting-edge immunoinformatics and molecular dynamics simulations to address the global challenge posed by influenza virus variability.

6 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RZRong Zhu
Rong Zhu
WHWeijin Huang
Weijin Huang
WWWenbo Wang
Wenbo Wang
QLQiang Liu
Qiang Liu
JNJianhui Nie
Jianhui Nie
YWYouchun Wang
Youchun Wang
The vaccinia virus Guang9 strain (VG9), derived from the vaccinia virus Tian Tan strain (VTT) has been found to be less virulent than VTT. To investigate whether VG9 could be a potential replicating virus vector, the TK genes in VG9 and VTT were replaced with the HIV-1 envelope gene via homologous recombination, resulting in the recombinant viruses, VG9-E and VTT-E. The biology, virulence, humoral and cellular immunological responses of VG9-E and VTT-E were evaluated. Our results indicated no obvious difference in range of host cells and diffusion between two recombinant viruses. Neurovirulence for VG9-E in weanling and suckling mice, and skin virulence in rabbits, were lower than that of VTT-E. The humoral immune responses, including binding antibody and neutralizing antibody responses, induced by VG9-E were not significantly different from those for VTT-E whilst IFN-γ response which represented cellular immune response induced by VG9-E was significantly higher than that did by VTT-E. Our results indicated that VG9-E was less virulent, yet induced higher cellular immune response than VTT-E. Therefore, it could be an ideal replicating vaccinia vector for HIV vaccine research and development.